$3.05
-0.04 (-1.29%)
Open$3.05
Previous Close$3.09
Day High$3.20
Day Low$2.90
52W High$1,030.00
52W Low—
Volume—
Avg Volume95.2K
Market Cap54.93M
P/E Ratio—
EPS$-4.14
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+266.9% upside
Current
$3.05
$3.05
Target
$11.19
$11.19
$8.32
$11.19 avg
$14.48
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.88M | 4.46M | 5.44M |
| Net Income | -169,945 | -168,167 | -171,039 |
| Profit Margin | -3.5% | -3.8% | -3.2% |
| EBITDA | -214,177 | -200,655 | -244,682 |
| Free Cash Flow | -155,731 | -123,018 | -136,236 |
| Rev Growth | -8.5% | +21.3% | +21.2% |
| Debt/Equity | 0.77 | 0.64 | 0.80 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |